Lu Zhang

Lu Zhang

Auto-generated profile, based on publicly available information

Lu Zhang

National Research Institute for Family Planning, Beijing 100081, China; National Human Genetic Resources Center, Beijing 102206, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2024 in Molecular Therapy
Verified
Journal Article
Open access
LZLu Zhang
Lu Zhang
KLKai Li
Kai Li
ZLZhiwei Liu
Zhiwei Liu
LALisha An
Lisha An
HWHaikun Wei
Haikun Wei
XMXu Ma
Xu Ma
Base editing of hematopoietic stem/progenitor cells (HSPCs) is an attractive strategy for treating immunohematologic diseases. However, the feasibility of using adenine base-edited HSPCs for treating X-linked severe combined immunodeficiency (SCID-X1), the influence of dose-response relationships on immune cell generation, and the potential risks have not been demonstrated in vivo. Here, a humanized SCID-X1 mouse model was established and 86.67% ± 2.52% (n = 3) of mouse hematopoietic stem cell (HSC) pathogenic mutations were corrected, with no sgRNA-dependent off-target effects detected. Analysis of peripheral blood over 16 weeks post-transplantation in mice with different immunodeficiency backgrounds revealed efficient immune cell generation following transplantation of different amounts of modified HSCs. Therefore, a large-scale infusion of gene-corrected HSCs within a safe range can achieve rapid, stable, and durable immune cells regeneration. Tissue section staining further demonstrated the restoration of immune organ tissue structures, with no tumor formation in multiple organs. Collectively, these data suggest that base-edited HSCs are a potential therapeutic approach for SCID-X1 and that a threshold infusion dose of gene-corrected cells is required for immune cell regeneration. This study lays a theoretical foundation for the clinical application of base-edited HSCs in treating SCID-X1.

1 February 2022 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
XJXiaohua Jin
Xiaohua Jin
LZLu Zhang
Lu Zhang
XWXinjie Wang
Xinjie Wang
LALisha An
Lisha An
SHShasha Huang
Shasha Huang
XMXu Ma
Xu Ma